118 related articles for article (PubMed ID: 11809341)
1. The influence of tibolone on quality of life in postmenopausal women.
Meeuwsen IB; Samson MM; Duursma SA; Verhaar HJ
Maturitas; 2002 Jan; 41(1):35-43. PubMed ID: 11809341
[TBL] [Abstract][Full Text] [Related]
2. Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients--data from LIBERATE trial.
Sismondi P; Kimmig R; Kubista E; Biglia N; Egberts J; Mulder R; Planellas J; Moggio G; Mol-Arts M; Kenemans P
Maturitas; 2011 Dec; 70(4):365-72. PubMed ID: 22030384
[TBL] [Abstract][Full Text] [Related]
3. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms.
Hammar M; Christau S; Nathorst-Böös J; Rud T; Garre K
Br J Obstet Gynaecol; 1998 Aug; 105(8):904-11. PubMed ID: 9746385
[TBL] [Abstract][Full Text] [Related]
4. Tibolone relieves climacteric symptoms in highly symptomatic women with at least seven hot flushes and sweats per day.
Landgren MB; Helmond FA; Engelen S
Maturitas; 2005 Mar; 50(3):222-30. PubMed ID: 15734603
[TBL] [Abstract][Full Text] [Related]
5. The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial.
Kroiss R; Fentiman IS; Helmond FA; Rymer J; Foidart JM; Bundred N; Mol-Arts M; Kubista E
BJOG; 2005 Feb; 112(2):228-33. PubMed ID: 15663589
[TBL] [Abstract][Full Text] [Related]
6. Dose-response analysis of effects of tibolone on climacteric symptoms.
Landgren MB; Bennink HJ; Helmond FA; Engelen S
BJOG; 2002 Oct; 109(10):1109-14. PubMed ID: 12387462
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of oral tibolone 1.25 or 2.5 mg/day vs. placebo in postmenopausal women.
Hudita D; Posea C; Ceausu I; Rusu M
Eur Rev Med Pharmacol Sci; 2003; 7(5):117-25. PubMed ID: 15214586
[TBL] [Abstract][Full Text] [Related]
8. Short and long term effects of tibolone in postmenopausal women.
Formoso G; Perrone E; Maltoni S; Balduzzi S; D'Amico R; Bassi C; Basevi V; Marata AM; Magrini N; Maestri E
Cochrane Database Syst Rev; 2012 Feb; (2):CD008536. PubMed ID: 22336846
[TBL] [Abstract][Full Text] [Related]
9. Tibolone in the treatment of psychosomatic symptoms in menopause.
Argyroudis EM; Iatrakis G; Kourkoubas A; Georgoulias N; Kourounis G; Tsionis C; Prapa Z; Karamanos K; Diakakis I; Giannikos L; Ladopoulos J
Clin Exp Obstet Gynecol; 1997; 24(3):167-8. PubMed ID: 9478309
[TBL] [Abstract][Full Text] [Related]
10. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study.
Swanson SG; Drosman S; Helmond FA; Stathopoulos VM
Menopause; 2006; 13(6):917-25. PubMed ID: 17006377
[TBL] [Abstract][Full Text] [Related]
11. The effects of tibolone on vaginal blood flow, sexual desire and arousability in postmenopausal women.
Laan E; van Lunsen RH; Everaerd W
Climacteric; 2001 Mar; 4(1):28-41. PubMed ID: 11379375
[TBL] [Abstract][Full Text] [Related]
12. Muscle strength and tibolone: a randomised, double-blind, placebo-controlled trial.
Meeuwsen IB; Samson MM; Duursma SA; Verhaar HJ
BJOG; 2002 Jan; 109(1):77-84. PubMed ID: 11845814
[TBL] [Abstract][Full Text] [Related]
13. Double-blind, placebo-controlled study of the effects of tibolone on bone mineral density in postmenopausal osteoporotic women with and without previous fractures.
Pavlov PW; Ginsburg J; Kicovic PM; van der Schaaf DB; Prelevic G; Bennink HJ
Gynecol Endocrinol; 1999 Aug; 13(4):230-7. PubMed ID: 10533157
[TBL] [Abstract][Full Text] [Related]
14. [Our experience in the treatment of climacteric complaints with Livial (Organon)].
Pekhlivanov B; Malinova M; Milchev N
Akush Ginekol (Sofiia); 2001; 40(4):16-7. PubMed ID: 11803863
[TBL] [Abstract][Full Text] [Related]
15. Effects of tibolone and continuous combined conjugated equine estrogen/medroxyprogesterone acetate on the endometrium and vaginal bleeding: results of the OPAL study.
Langer RD; Landgren BM; Rymer J; Helmond FA;
Am J Obstet Gynecol; 2006 Nov; 195(5):1320-7. PubMed ID: 16875644
[TBL] [Abstract][Full Text] [Related]
16. Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms.
Bouchard P; Panay N; de Villiers TJ; Vincendon P; Bao W; Cheng RJ; Constantine G
Climacteric; 2012 Feb; 15(1):12-20. PubMed ID: 22066790
[TBL] [Abstract][Full Text] [Related]
17. A randomized, placebo-controlled, crossover study of tibolone (Livial) on menopause symptoms, psychological well-being, and dyadic relationship of postmenopausal Chinese women and their spouses.
Lam PM; Cheung GW; Shek DT; Lee DT; Haines CJ; Chung TK
Menopause; 2004; 11(4):416-22. PubMed ID: 15243279
[TBL] [Abstract][Full Text] [Related]
18. Effects of a continuous-combined regimen of low-dose hormone therapy (oestradiol and norethindrone acetate) and tibolone on the quality of life in symptomatic postmenopausal women: a double-blind, randomised study.
Polisseni AF; Andrade AT; Ribeiro LC; Castro IQ; Brandão M; Polisseni F; Guerra Mde O
Maturitas; 2013 Feb; 74(2):172-8. PubMed ID: 23201326
[TBL] [Abstract][Full Text] [Related]
19. Effects of tibolone on auditory brainstem responses in postmenopausal women--a randomized, double-blind, placebo-controlled trial.
Sator MO; Franz P; Egarter C; Gruber DM; Wölfl G; Nagele F
Fertil Steril; 1999 Nov; 72(5):885-8. PubMed ID: 10560994
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial.
Kenemans P; Bundred NJ; Foidart JM; Kubista E; von Schoultz B; Sismondi P; Vassilopoulou-Sellin R; Yip CH; Egberts J; Mol-Arts M; Mulder R; van Os S; Beckmann MW;
Lancet Oncol; 2009 Feb; 10(2):135-46. PubMed ID: 19167925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
